Reciprocal relation of thyroid-stimulating hormone and thyroid-stimulating immunoglobulin in a patient with endogenous subclinical hyperthyroidism

American Journal of the Medical Sciences

Volumn 333, Issue 5, 2007, Pages 296-299

  Premachandra, B N ^a,b   Radparvar, A ^c   Williams, I K ^a  

^a Thyroid Specialty Laboratory   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c Missouri Endocr and Diabetes Ctr   (United States)

Author keywords

Subclinical hyperthyroidism; TSI and TSH reciprocal relation; TSI in subclinical hyperthyroidism

Indexed keywords

THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN; THYROXINE;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL OBSERVATION; ENDOCRINE OPHTHALMOPATHY; FEMALE; FREE THYROXINE INDEX; GOITER; HUMAN; HYPERTHYROIDISM; LABORATORY TEST; PHYSICAL EXAMINATION; SUBCLINICAL HYPERTHYROIDISM; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

AGED; FEMALE; HUMANS; HYPERTHYROIDISM; IMMUNOGLOBULINS, THYROID-STIMULATING; THYROTROPIN;

EID: 34249055959     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318053e17c     Document Type: Article

References (14)

1. Surks M, Ortiz E, Daniels GH, et al. Subclinical thyroid disease. JAMA 2004;291:228-38.
2. Shrier DK, Burman KD. Subclinical hyperthyroidism: controversies in management. Am Fam Physician 2002;65:4331-8.
3. Haden ST, Marqusee E, Utiger RD. Subclinical hyperthyroidism. Endocrinologist 1996;6:322-7.
4. Premachandra BN, Wortsman J, Willliams IK. Inhibition of serum protein binding of thyroxine in a hypothyroid patient with familial dysalbuminemic hyperthyroxinemia. Clin Biochem 1996;29:85-8.
5. th ed., Philadelphia, WB Saunders; 1981;p. 117-247.
6. Dorfman SG, Cooperman MT, Nelson RL, et al. Painless thyroiditis and transient hyperthyroidism without goiter. Ann Intern Med 1977;86:24-8.
7. Ross DS. Subclinical thyrotoxicosis. In: Braverman LE, Utiger RD. Editors. The Thyroid. 8th ed. Lippincott; 2000;p. 1007-12.
8. Parle IV, Franklyn JA, Cross KW, et al. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol 1991;34:77-83.
9. Creagh F, Howell RD, Williams S, et al. IgG thyrotrophin receptor antibody activity in Graves' disease: a study of TSH agonist and antagonist activities by isoelectric focusing. Clin Endocrinol 1986;24:79-88.
10. th Annual Meeting of Clinical Endocrinologists. 1999.
11. Kasagi K, Takeuchi R, Misaki T, et al. Subclinical Graves' disease as a cause of subnormal TSH levels in euthyroid subjects. J Endocrinol Invest 1997;20:183-8.
12. Ross DS, Daniels GH, Gouveia D. The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic. J Clin Endocrinol Metab 1990;71:764-9.
13. Brokken LJS, Scheenhart JWC, Wiersinga WM, et al. Suppression of serum TSH by Graves' Ig: evidence for a functional pituitary TSH receptor. J Clin Endocrinol Metab 2001;86:4814-7.
14. Brokken LJS, Wiersinga WM, Prummel MF. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients. J Clin Endocrinol Metab 2003;88:4135-8.